Regenxbio Inc. (NASDAQ:RGNX) Q3 2019 Earnings Conference Call - Final Transcript
Nov 05, 2019 • 04:30 pm ET
Good afternoon and welcome to the REGENXBIO Third Quarter 2019 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Mr. Patrick Christmas, Senior Vice President and General Counsel for REGENXBIO. You may begin.
Patrick J. Christmas
Good afternoon and thank you for joining us today. With us are Ken Mills, REGENXBIO's President and Chief Executive Officer; Dr. Steve Pakola, our Chief Medical Officer; and Vit Vasista, our Chief Financial Officer. Earlier this afternoon REGENXBIO released financial and operating results for the three months ended September 30th, 2019. The press release reporting our financial results is available on our website at www.regenxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning.
Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors in the Management's Discussion and Analysis sections of REGENXBIO's quarterly report on Form 10-Q for the quarter ended September 30th, 2019, which is on file with the Securities and Exchange Commission and available on the SEC's website.
Any information we provide on this conference call is provided only as of the date of this call, November 5th, 2019 and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.
I would now like to turn the call over to Ken Mills, President and Chief Executive Officer of REGENXBIO.
Thank you, Patrick. Good afternoon everyone and thanks for joining us on today's conference call. We'll provide a recap of our recent progress advancing and expanding our NAV Technology Platform. Steve, will provide an overview of the RGX-314 data presented at AAO, and an update on our clinical programs, and Vit will provide an update on financial results for the third quarter of 2019. We'll then open the call for questions.
Over the course of the past decade, REGENXBIO's mission has remained clear, to improve lives through the curative potential of gene therapy based on our proprietary NAV Technology Platform. We believe single administration gene therapy treatments can significantly alter the course of disease in many patient populations and we are committed to work -- to our work with these patients in mind. We continue to advance and broaden our pipeline across two treatment modalities, AAV-mediated antibody delivery and monogenic gene replacement. Both, modalities utilize our NAV